Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about dU: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
| Target | Relation | Type | Str |
|---|---|---|---|
| No outgoing edges | |||
| Source | Relation | Type | Str |
|---|---|---|---|
| HNRNPD | binds | protein | 0.80 |
Hypotheses where this entity is a therapeutic target
Scientific analyses that reference this entity
No analyses mention this entity
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| Plant-based dietary patterns and Alzheimer's disease risk in multiethn | clinical | Alzheimer's disease and relate | 0.950 | 0.00 | human patients | proposed | N/A |
| CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs AD with Co | clinical | Alzheimer's Disease | 0.900 | 0.50 | aortic endothelial cells | proposed | $6,550,000 |
| Resveratrol protection against renal I/R injury in diabetic rats | validation | diabetic nephropathy | 0.900 | 0.00 | streptozotocin-induced diabeti | proposed | N/A |
| TLR expression analysis in Parkinson's disease patients | clinical | Parkinson's disease | 0.850 | 0.00 | human patients | proposed | N/A |
| Resveratrol effects on HK-2 cells under hypoxia/reoxygenation | exploratory | diabetic nephropathy | 0.850 | 0.00 | HK-2 cells cultured in high gl | proposed | N/A |
| TLR4 Activation Assay with NETs and Anti-CarP Antibodies | exploratory | rheumatoid arthritis | 0.850 | 0.00 | HEK293 TLR4 reporter cells | proposed | N/A |
| TLR expression in α-synuclein overexpressing mice | validation | Parkinson's disease | 0.800 | 0.00 | mice overexpressing human α-sy | proposed | N/A |
| s:** - Test tau spreading in AQP4 knockout vs wild-type mice with PSP/ | falsification | Neurodegeneration | 0.400 | 0.50 | mouse | proposed | $260,000 |
| Circadian-Vascular-Metabolic Syndrome (CVMS) Intervention Trial | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $3,900,000 |
| DLB Cognitive Fluctuation Mechanism Experiment | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Glymphatic-Circadian Axis Enhancement Therapy for Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Non-Motor Symptom Progression in Parkinson's Disease — Mechanisms and | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| NPH Glymphatic System Interaction Experiment | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Sleep and Circadian Dysfunction as Driver of Neurodegeneration | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Sleep Disruption and Alzheimer's Disease — mechanism and intervention | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Sleep and Respiratory Network Interaction in ALS — Experiment Design | clinical | ALS | 0.400 | 0.50 | human | proposed | $5,460,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Combined effects of HCRTR1/2 gene variants and non-genetic factors on sleep-wake [PMID:40439868] | Zheng Z, Xue F, Wang H, Gu Q, Hu R, Li X | Pharmacol Rep | 2025 | 1 |
| Microglia-Mediated Neuroinflammation: A Potential Target for the Treatment of Ca [PMID:35642214] | Wang M, Pan W, Xu Y, Zhang J, Wan J, Jia | J Inflamm Res | 2022 | 1 |
| Genetic determinants of daytime napping and effects on cardiometabolic health. [PMID:33568662] | Dashti HS, Daghlas I, Lane JM, Huang Y, | Nat Commun | 2021 | 1 |
| Hypocretin/Orexin Receptor Pharmacology and Sleep Phases. [PMID:34052813] | Sun Y, Tisdale RK, Kilduff TS | Front Neurol Neurosci | 2021 | 1 |
| Sleep drives metabolite clearance from the adult brain. [PMID:24136970] | Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Th | Science | 2013 | 1 |
| Podocyte TLR4 deletion alleviates diabetic kidney disease through prohibiting PK [PMID:40659086] | Li Z, Tan D, Lin J, Zhang T, Liu B et al | J Adv Res | 2026 | 0 |
| Celastrol treatment attenuates the inflammatory response in Alzheimer's disease [PMID:40762111] | Cao F, Zhang P, Zheng Z, Wang P, Wang Y | Neurol Res | 2026 | 0 |
| Integrative Multiomics Insights into the Genetic and Epigenetic Architecture of [PMID:41422555] | Mishra AK, Jain S | ACS Chem Neurosci | 2026 | 0 |
| CircCramp1l targets the miR-532-3p/HMGB1/Drp1 axis to regulate allergic rhinitis [PMID:41519399] | Zhang Y, Wang J, Song Y, Chai J, Li L et | Biochem Pharmacol | 2026 | 0 |
| The association of Alzheimer's disease-related SNPs with mild cognitive impairme [PMID:41606232] | Xie Z, Tu W, Ye XF, Hua L, Zhang X et al | Sci Rep | 2026 | 0 |
| Genetic risk factors of late-onset Alzheimer's disease: Insights into pathophysi [PMID:41622452] | Akkaoui J, Devadoss D, Rodriguez MD, Ari | Neural Regen Res | 2026 | 0 |
| Neuronal TLR4 upregulation activates the cGAS-STING pathway to induce ferroptosi [PMID:41702081] | Qin H, Yang L, Du J, Xu X, Chen Z et al. | Int Immunopharmacol | 2026 | 0 |
| Genetic Burden and <i>APOE</i> Methylation in a Korean Multi-Generational Alzhei [PMID:41745359] | Eom Je-Hyun; Cho Mu-Yeol; Kim Ji-Won; Ki | Journal of personalized medici | 2026 | 0 |
| Genetic Architecture of Cognitive Resilience in Alzheimer's Disease: Mechanisms, [PMID:41893052] | Burdman Gabriel; Akkaoui Juliet; Colon N | Neurology international | 2026 | 0 |
| 2'-Fucosyllactose Alleviates Metabolic Hypertension in Mice via Gut Microbiota M [PMID:41926238] | Chen J, Liang S, Liu D, Yang S, Yan Q et | J Agric Food Chem | 2026 | 0 |
| Leveraging intraperitoneal delivery of toll-like receptor agonists to treat peri [PMID:41926324] | Yan H, Chia D, Ernst S, Demuytere J, Cos | Expert Opin Drug Deliv | 2026 | 0 |
| Small-molecule PCSK9 inhibition enhances BBB amyloid-β clearance and suppresses [PMID:41927877] | Miao J, Wang J, Zhou W, Guo J | Sci Rep | 2026 | 0 |
| Anti-carbamylated protein antibodies stabilize carbamylated Histone H3 to promot [PMID:41930627] | Nakabo S, Hanata N, Patino-Martinez E, H | Arthritis Rheumatol | 2026 | 0 |
| In silico design of a novel multi-epitope mRNA vaccine candidate for BtHKU5-CoV- [PMID:41931545] | Zheng N, Xu Y | PLoS Negl Trop Dis | 2026 | 0 |
| Upstream ORFs control TNFR1 abundance and tissue tolerance to TNF. [PMID:41931597] | Ma B, Lyu W, Rizk J, Han X, Kjær M et al | Sci Immunol | 2026 | 0 |
Multi-agent debates referencing this entity
No debates reference this entity
Hypotheses and analyses mentioning dU in their description or question text
Score: 0.811 · neurodegeneration · 2026-04-16
## Mechanistic Overview CLU/APOE Duality in Amyloid Clearance Determines Cell-Type-Specific Vulnerability Thresholds sta
Score: 0.790 · protein biochemistry · 2026-04-21
## **Molecular Mechanism and Rationale** The recognition of amyloidogenic protein species by the heat shock protein 70
Score: 0.789 · neurodegeneration · 2026-04-02
## Mechanistic Overview Selective TLR4 Modulation to Prevent Gut-Derived Neuroinflammatory Priming starts from the claim
Score: 0.780 · neurodegeneration · 2026-04-22
## Mechanistic Overview Sleep-Dependent Glymphatic Clearance Expands the Therapeutic Window by Reducing Extracellular Ta
Score: 0.778 · neurodegeneration · 2026-04-16
## Mechanistic Overview SIRT1/PGC-1α Axis Activation to Preserve Mitochondrial Resiliency Against Microbiome-Induced Neu
Score: 0.774 · neuroscience · 2026-04-07
## Mechanistic Overview Dual-Circuit Tau Vulnerability Cascade starts from the claim that modulating MAPT within the dis
Score: 0.773 · neurodegeneration · 2026-04-02
## Mechanistic Overview Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modulation starts from the claim that mo
Score: 0.768 · neurodegeneration · 2026-04-02
## Mechanistic Overview Chromatin Accessibility Restoration via BRD4 Modulation starts from the claim that modulating BR
Score: 0.752 · neuroinflammation · 2026-04-15
## Mechanistic Overview Temporal SPP1 Inhibition During Critical Windows starts from the claim that modulating SPP1 with
Score: 0.752 · lipidomics · 2026-04-25
The hypothesis proposes that ω-3 docosahexaenoic acid (DHA) is metabolized by CYP2J2 to generate protective epoxides tha
Score: 0.750 · neurodegeneration · 2026-04-25
The most actionable synthesis is that pathogenicity may depend more on conversion of C1q binding into classical-pathway
Score: 0.750 · neurodegeneration · 2026-04-02
## Mechanistic Overview Selective Acid Sphingomyelinase Modulation Therapy starts from the claim that modulating SMPD1 w